In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor
Rationale The lack of potent, selective, brain penetrant Y 2 receptor antagonists has hampered in vivo functional studies of this receptor. Objective Here, we report the in vitro and in vivo characterization of JNJ-31020028 ( N -(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophe...
Gespeichert in:
Veröffentlicht in: | Psychopharmacology 2010-02, Vol.208 (2), p.265-277 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 277 |
---|---|
container_issue | 2 |
container_start_page | 265 |
container_title | Psychopharmacology |
container_volume | 208 |
creator | Shoblock, James R. Welty, Natalie Nepomuceno, Diane Lord, Brian Aluisio, Leah Fraser, Ian Motley, S. Timothy Sutton, Steve W. Morton, Kirsten Galici, Ruggero Atack, John R. Dvorak, Lisa Swanson, Devin M. Carruthers, Nicholas I. Dvorak, Curt Lovenberg, Timothy W. Bonaventure, Pascal |
description | Rationale
The lack of potent, selective, brain penetrant Y
2
receptor antagonists has hampered in vivo functional studies of this receptor.
Objective
Here, we report the in vitro and in vivo characterization of JNJ-31020028 (
N
-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y
2
receptor antagonist.
Methods
The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y
2
receptors in KAN-Ts cells and rat Y
2
receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y
2
bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.
Results
JNJ-31020028 bound with high affinity (pIC
50
= 8.07 ± 0.05, human, and pIC
50
= 8.22 ± 0.06, rat) and was >100-fold selective versus human Y
1
, Y
4
, and Y
5
receptors. JNJ-31020028 was demonstrated to be an antagonist (pK
B
= 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y
2
receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.
Conclusion
These results suggest that Y
2
receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions. |
doi_str_mv | 10.1007/s00213-009-1726-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_218965365</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1935427661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</originalsourceid><addsrcrecordid>eNp1UU1r3DAUFKWFbrf9Ab2JnjZQpU-S12sfS0jzQUgv7SGUYmT5OavglVxJXtYb-rdzjlwXeqoQiKd5M_OkIeQ9h1MOsPkUAASXDKBkfCNydnhBFjyTggnYiJdkASAlk3xdvCZvQniAtLIiW5CnK0v3JnpHlW2omYq9o3qrvNIRvTmqaJylrqXXt9dJAEQyKujqlq0y9pixH4KtGoNxO3ZqZ6w7YYK5g2Oc9Vu0Y_cH-dmbHr06Gpvux-43k6ztBufd3DNx-tGbJuEy4TXaYxJr8OQjVTRghzqaPdLaqzRgjxajVzbSsFNdR3cu4UOH6QFR3TtrQpzGjVukFofkgX1MWvSO3gnqUafS-bfkVau6gO_-nkvy_cv5t7NLdvP14urs8w3TQsKBZa2AJs_LAlEBNmuetZiBxrwWqmwFYoNK59DUjWhBKCxazLUo0w-puhBayiX5MOv23v0aMMTqwQ3eJstK8KLM1zLtJeFzk_YuBI9t1XuzU36sOFRTutWcbpXSraZ0q0PiiJkTUq-9R_9P-P-kZ4YNq6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218965365</pqid></control><display><type>article</type><title>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</title><source>SpringerLink Journals</source><creator>Shoblock, James R. ; Welty, Natalie ; Nepomuceno, Diane ; Lord, Brian ; Aluisio, Leah ; Fraser, Ian ; Motley, S. Timothy ; Sutton, Steve W. ; Morton, Kirsten ; Galici, Ruggero ; Atack, John R. ; Dvorak, Lisa ; Swanson, Devin M. ; Carruthers, Nicholas I. ; Dvorak, Curt ; Lovenberg, Timothy W. ; Bonaventure, Pascal</creator><creatorcontrib>Shoblock, James R. ; Welty, Natalie ; Nepomuceno, Diane ; Lord, Brian ; Aluisio, Leah ; Fraser, Ian ; Motley, S. Timothy ; Sutton, Steve W. ; Morton, Kirsten ; Galici, Ruggero ; Atack, John R. ; Dvorak, Lisa ; Swanson, Devin M. ; Carruthers, Nicholas I. ; Dvorak, Curt ; Lovenberg, Timothy W. ; Bonaventure, Pascal</creatorcontrib><description>Rationale
The lack of potent, selective, brain penetrant Y
2
receptor antagonists has hampered in vivo functional studies of this receptor.
Objective
Here, we report the in vitro and in vivo characterization of JNJ-31020028 (
N
-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y
2
receptor antagonist.
Methods
The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y
2
receptors in KAN-Ts cells and rat Y
2
receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y
2
bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.
Results
JNJ-31020028 bound with high affinity (pIC
50
= 8.07 ± 0.05, human, and pIC
50
= 8.22 ± 0.06, rat) and was >100-fold selective versus human Y
1
, Y
4
, and Y
5
receptors. JNJ-31020028 was demonstrated to be an antagonist (pK
B
= 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y
2
receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.
Conclusion
These results suggest that Y
2
receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.</description><identifier>ISSN: 0033-3158</identifier><identifier>EISSN: 1432-2072</identifier><identifier>DOI: 10.1007/s00213-009-1726-x</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Antagonist drugs ; Biomedical and Life Sciences ; Biomedicine ; Neurosciences ; Neurotransmitters ; Original Investigation ; Pharmacology/Toxicology ; Psychiatry ; Psychopharmacology ; Rodents</subject><ispartof>Psychopharmacology, 2010-02, Vol.208 (2), p.265-277</ispartof><rights>Johnson and Johnson Pharmaceutical Research and Development, L.L.C. 2009</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</citedby><cites>FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00213-009-1726-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00213-009-1726-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Shoblock, James R.</creatorcontrib><creatorcontrib>Welty, Natalie</creatorcontrib><creatorcontrib>Nepomuceno, Diane</creatorcontrib><creatorcontrib>Lord, Brian</creatorcontrib><creatorcontrib>Aluisio, Leah</creatorcontrib><creatorcontrib>Fraser, Ian</creatorcontrib><creatorcontrib>Motley, S. Timothy</creatorcontrib><creatorcontrib>Sutton, Steve W.</creatorcontrib><creatorcontrib>Morton, Kirsten</creatorcontrib><creatorcontrib>Galici, Ruggero</creatorcontrib><creatorcontrib>Atack, John R.</creatorcontrib><creatorcontrib>Dvorak, Lisa</creatorcontrib><creatorcontrib>Swanson, Devin M.</creatorcontrib><creatorcontrib>Carruthers, Nicholas I.</creatorcontrib><creatorcontrib>Dvorak, Curt</creatorcontrib><creatorcontrib>Lovenberg, Timothy W.</creatorcontrib><creatorcontrib>Bonaventure, Pascal</creatorcontrib><title>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</title><title>Psychopharmacology</title><addtitle>Psychopharmacology</addtitle><description>Rationale
The lack of potent, selective, brain penetrant Y
2
receptor antagonists has hampered in vivo functional studies of this receptor.
Objective
Here, we report the in vitro and in vivo characterization of JNJ-31020028 (
N
-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y
2
receptor antagonist.
Methods
The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y
2
receptors in KAN-Ts cells and rat Y
2
receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y
2
bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.
Results
JNJ-31020028 bound with high affinity (pIC
50
= 8.07 ± 0.05, human, and pIC
50
= 8.22 ± 0.06, rat) and was >100-fold selective versus human Y
1
, Y
4
, and Y
5
receptors. JNJ-31020028 was demonstrated to be an antagonist (pK
B
= 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y
2
receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.
Conclusion
These results suggest that Y
2
receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.</description><subject>Antagonist drugs</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Neurosciences</subject><subject>Neurotransmitters</subject><subject>Original Investigation</subject><subject>Pharmacology/Toxicology</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rodents</subject><issn>0033-3158</issn><issn>1432-2072</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp1UU1r3DAUFKWFbrf9Ab2JnjZQpU-S12sfS0jzQUgv7SGUYmT5OavglVxJXtYb-rdzjlwXeqoQiKd5M_OkIeQ9h1MOsPkUAASXDKBkfCNydnhBFjyTggnYiJdkASAlk3xdvCZvQniAtLIiW5CnK0v3JnpHlW2omYq9o3qrvNIRvTmqaJylrqXXt9dJAEQyKujqlq0y9pixH4KtGoNxO3ZqZ6w7YYK5g2Oc9Vu0Y_cH-dmbHr06Gpvux-43k6ztBufd3DNx-tGbJuEy4TXaYxJr8OQjVTRghzqaPdLaqzRgjxajVzbSsFNdR3cu4UOH6QFR3TtrQpzGjVukFofkgX1MWvSO3gnqUafS-bfkVau6gO_-nkvy_cv5t7NLdvP14urs8w3TQsKBZa2AJs_LAlEBNmuetZiBxrwWqmwFYoNK59DUjWhBKCxazLUo0w-puhBayiX5MOv23v0aMMTqwQ3eJstK8KLM1zLtJeFzk_YuBI9t1XuzU36sOFRTutWcbpXSraZ0q0PiiJkTUq-9R_9P-P-kZ4YNq6Y</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Shoblock, James R.</creator><creator>Welty, Natalie</creator><creator>Nepomuceno, Diane</creator><creator>Lord, Brian</creator><creator>Aluisio, Leah</creator><creator>Fraser, Ian</creator><creator>Motley, S. Timothy</creator><creator>Sutton, Steve W.</creator><creator>Morton, Kirsten</creator><creator>Galici, Ruggero</creator><creator>Atack, John R.</creator><creator>Dvorak, Lisa</creator><creator>Swanson, Devin M.</creator><creator>Carruthers, Nicholas I.</creator><creator>Dvorak, Curt</creator><creator>Lovenberg, Timothy W.</creator><creator>Bonaventure, Pascal</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>201002</creationdate><title>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</title><author>Shoblock, James R. ; Welty, Natalie ; Nepomuceno, Diane ; Lord, Brian ; Aluisio, Leah ; Fraser, Ian ; Motley, S. Timothy ; Sutton, Steve W. ; Morton, Kirsten ; Galici, Ruggero ; Atack, John R. ; Dvorak, Lisa ; Swanson, Devin M. ; Carruthers, Nicholas I. ; Dvorak, Curt ; Lovenberg, Timothy W. ; Bonaventure, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c230x-4f20d6698eea0ed514fe40ce6b2a9f2eedeac60dbd2f02ae8fe6c29028ab82c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antagonist drugs</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Neurosciences</topic><topic>Neurotransmitters</topic><topic>Original Investigation</topic><topic>Pharmacology/Toxicology</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shoblock, James R.</creatorcontrib><creatorcontrib>Welty, Natalie</creatorcontrib><creatorcontrib>Nepomuceno, Diane</creatorcontrib><creatorcontrib>Lord, Brian</creatorcontrib><creatorcontrib>Aluisio, Leah</creatorcontrib><creatorcontrib>Fraser, Ian</creatorcontrib><creatorcontrib>Motley, S. Timothy</creatorcontrib><creatorcontrib>Sutton, Steve W.</creatorcontrib><creatorcontrib>Morton, Kirsten</creatorcontrib><creatorcontrib>Galici, Ruggero</creatorcontrib><creatorcontrib>Atack, John R.</creatorcontrib><creatorcontrib>Dvorak, Lisa</creatorcontrib><creatorcontrib>Swanson, Devin M.</creatorcontrib><creatorcontrib>Carruthers, Nicholas I.</creatorcontrib><creatorcontrib>Dvorak, Curt</creatorcontrib><creatorcontrib>Lovenberg, Timothy W.</creatorcontrib><creatorcontrib>Bonaventure, Pascal</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shoblock, James R.</au><au>Welty, Natalie</au><au>Nepomuceno, Diane</au><au>Lord, Brian</au><au>Aluisio, Leah</au><au>Fraser, Ian</au><au>Motley, S. Timothy</au><au>Sutton, Steve W.</au><au>Morton, Kirsten</au><au>Galici, Ruggero</au><au>Atack, John R.</au><au>Dvorak, Lisa</au><au>Swanson, Devin M.</au><au>Carruthers, Nicholas I.</au><au>Dvorak, Curt</au><au>Lovenberg, Timothy W.</au><au>Bonaventure, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor</atitle><jtitle>Psychopharmacology</jtitle><stitle>Psychopharmacology</stitle><date>2010-02</date><risdate>2010</risdate><volume>208</volume><issue>2</issue><spage>265</spage><epage>277</epage><pages>265-277</pages><issn>0033-3158</issn><eissn>1432-2072</eissn><abstract>Rationale
The lack of potent, selective, brain penetrant Y
2
receptor antagonists has hampered in vivo functional studies of this receptor.
Objective
Here, we report the in vitro and in vivo characterization of JNJ-31020028 (
N
-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a novel Y
2
receptor antagonist.
Methods
The affinity of JNJ-31020028 was determined by inhibition of the PYY binding to human Y
2
receptors in KAN-Ts cells and rat Y
2
receptors in rat hippocampus. The functional activity was determined by inhibition of PYY-stimulated calcium responses in KAN-Ts cells expressing a chimeric G protein Gqi5 and in the rat vas deferens (a prototypical Y
2
bioassay). Ex vivo receptor occupancy was revealed by receptor autoradiography. JNJ-31020028 was tested in vivo with microdialysis, in anxiety models, and on corticosterone release.
Results
JNJ-31020028 bound with high affinity (pIC
50
= 8.07 ± 0.05, human, and pIC
50
= 8.22 ± 0.06, rat) and was >100-fold selective versus human Y
1
, Y
4
, and Y
5
receptors. JNJ-31020028 was demonstrated to be an antagonist (pK
B
= 8.04 ± 0.13) in functional assays. JNJ-31020028 occupied Y
2
receptor binding sites (~90% at 10 mg/kg) after subcutaneous administration in rats. JNJ-31020028 increased norepinephrine release in the hypothalamus, consistent with the colocalization of norepinephrine and neuropeptide Y. In a variety of anxiety models, JNJ-31020028 was found to be ineffective, although it did block stress-induced elevations in plasma corticosterone, without altering basal levels, and normalized food intake in stressed animals without affecting basal food intake.
Conclusion
These results suggest that Y
2
receptors may not be critical for acute behaviors in rodents but may serve modulatory roles that can only be elucidated under specific situational conditions.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><doi>10.1007/s00213-009-1726-x</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0033-3158 |
ispartof | Psychopharmacology, 2010-02, Vol.208 (2), p.265-277 |
issn | 0033-3158 1432-2072 |
language | eng |
recordid | cdi_proquest_journals_218965365 |
source | SpringerLink Journals |
subjects | Antagonist drugs Biomedical and Life Sciences Biomedicine Neurosciences Neurotransmitters Original Investigation Pharmacology/Toxicology Psychiatry Psychopharmacology Rodents |
title | In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y2 receptor |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A49%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20and%20in%20vivo%20characterization%20of%20JNJ-31020028%20(N-(4-%7B4-%5B2-(diethylamino)-2-oxo-1-phenylethyl%5Dpiperazin-1-yl%7D-3-fluorophenyl)-2-pyridin-3-ylbenzamide),%20a%20selective%20brain%20penetrant%20small%20molecule%20antagonist%20of%20the%20neuropeptide%20Y%20Y2%20receptor&rft.jtitle=Psychopharmacology&rft.au=Shoblock,%20James%20R.&rft.date=2010-02&rft.volume=208&rft.issue=2&rft.spage=265&rft.epage=277&rft.pages=265-277&rft.issn=0033-3158&rft.eissn=1432-2072&rft_id=info:doi/10.1007/s00213-009-1726-x&rft_dat=%3Cproquest_cross%3E1935427661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218965365&rft_id=info:pmid/&rfr_iscdi=true |